Unlocking Market Access with AI

Life Sciences DNA Podcast

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل عام واحد (one)

المحتوى المقدم من Levine Media Group. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Levine Media Group أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

TechSurge: Deep Tech VC Podcast

1
Understanding the Elegant Math Behind Modern Machine Learning 1:14:43

منذ 11 يومًا1:14:43

التشغيل لاحقا

قوائم

إعجاب

احب

1:14:43

Artificial intelligence is evolving at an unprecedented pace—what does that mean for the future of technology, venture capital, business, and even our understanding of ourselves? Award-winning journalist and writer Anil Ananthaswamy joins us for our latest episode to discuss his latest book Why Machines Learn: The Elegant Math Behind Modern AI . Anil helps us explore the journey and many breakthroughs that have propelled machine learning from simple perceptrons to the sophisticated algorithms shaping today’s AI revolution, powering GPT and other models. The discussion aims to demystify some of the underlying mathematical concepts that power modern machine learning, to help everyone grasp this technology impacting our lives–even if your last math class was in high school. Anil walks us through the power of scaling laws, the shift from training to inference optimization, and the debate among AI’s pioneers about the road to AGI—should we be concerned, or are we still missing key pieces of the puzzle? The conversation also delves into AI’s philosophical implications—could understanding how machines learn help us better understand ourselves? And what challenges remain before AI systems can truly operate with agency? If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits. Links: Read Why Machines Learn, Anil’s latest book on the math behind AI https://www.amazon.com/Why-Machines-Learn-Elegant-Behind/dp/0593185749 Learn more about Anil Ananthaswamy’s work and writing https://anilananthaswamy.com/ Watch Anil Ananthaswamy’s TED Talk on AI and intelligence https://www.ted.com/speakers/anil_ananthaswamy Discover the MIT Knight Science Journalism Fellowship that shaped Anil’s AI research https://ksj.mit.edu/ Understand the Perceptron, the foundation of neural networks https://en.wikipedia.org/wiki/Perceptron Read about the Perceptron Convergence Theorem and its significance https://www.nature.com/articles/323533a0…

منذ عام واحد 53:38

MP3•منزل الحلقة

Rick Lloyd, founder and senior healthcare advisor of Range Health Advisors, sits down with Amar Drawid to discuss the intricacies of market access in the pharmaceutical industry, the importance of data analytics and AI in navigating the complexities of pricing and reimbursement, and how real-world evidence may help address the challenges faced by patients and healthcare providers in accessing medications.

21 حلقات

#Science #Biology #Business #Levine Media Group

Unlocking Market Access with AI

Life Sciences DNA Podcast

published منذ عام واحد

MP3•منزل الحلقة

21 حلقات

#Science #Biology #Business #Levine Media Group

كل الحلقات

1
Integrating AI into Precision Medicine 39:21

منذ 11 يومًا39:21

39:21

Tobias Guennel, senior vice president of product innovation and co-founder of QuartzBio, joins Nagaraja Srivatsan to discuss his insights on leveraging AI and advanced analytics to improve clinical trial efficiency, the integration of AI in precision medicine, and the use of AI agents to automate clinical trial operations.…

1
Transforming Clinical Development with AI 35:07

منذ 25 يومًا35:07

35:07

Bhaskar Sambasivan, CEO of Saama, sits down with Nagaraja Srivatsan to discuss the transformative role of AI in clinical development, why AI adoption will be a CEO mandate, and why the future of AI in drug development will be about autonomous decision-making.

1
Generating Proteins Nature Never Imagined 1:05:44

منذ 13 weeks1:05:44

1:05:44

Mike Nally, CEO of Generate Biomedicines, sits down with Amar Drawid to discuss the innovative use of generative AI in drug discovery, how the company’s platform integrates machine learning with biological engineering to create new therapeutic proteins, and the potential of generative AI to create more effective therapies for cancer and infectious diseases.…

1
Why Data Strategy Must Be Tied to Business Outcomes 58:38

منذ 15 weeks58:38

58:38

Kannan Raman of Amazon Web Service sits down with Amar Drawid to discuss the role of AI in transforming life sciences and the importance of data strategy being tied to business outcomes. They explore the challenges of data strategy, the importance of cultural shifts within organizations, and the monetization of data as a product.…

1
Biopharma Companies Wrestle with an Outsized Demand for AI Talent 48:54

منذ 17 weeks48:54

48:54

The increasing demand for AI talent in the life sciences industry is presenting a challenge for biopharma HR departments. Companies must compete for skilled workers not only against their competitors but also against tech firms that often offer more attractive compensation packages. Steve Swan, CEO of The Swan Group, sat down with Amar Drawid to discuss the current recruitment landscape for AI talent in the life sciences sector, the challenges companies are encountering, and why the mission of drug developers might give them a competitive advantage over tech companies in appealing to certain candidates.…

1
Using AI and Synthetic Biology to Go Where Antibody Therapies Can’t 57:58

منذ 20 weeks57:58

57:58

Monoclonal antibodies have been an important addition to the biomedical arsenal, but these therapies have limited ability to target a group of cell surface receptors known as GPCRs. Aikium is developing a new class of therapies known as SeqR proteins that offer an alternative to antibody-based drugs and can bind to intrinsically disordered regions of targeted GPCRs that were previously considered undruggable. Venkatesh Mysore, co-founder and CTO of Aikium, sits down with Amar Drawid to discuss how the company is using AI and synthetic biology to discover SeqR protein therapeutics to treat cancer, auto-immune diseases, and neuro-inflammatory disorders.…

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.